The thromboresistant mechanism of Heparin Surface and its application to membrane oxygenator
肝素表面抗血栓机制及其在膜式氧合器中的应用
基本信息
- 批准号:02670687
- 负责人:
- 金额:$ 1.6万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1990
- 资助国家:日本
- 起止时间:1990 至 1992
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
It is quite an important issue to prevent thrombus formation,i.e. to maitain anticoagulation in the clinical management of an extracorporeal circulation, such as a cardiopulmonary bypass in the cardovascular surgery. Although a surface-heparinized circuit, a newly developed thromboresistant material, has been reported to be effective to maintain anticoagulation during the extracorporeal circulation, it has not yet been introduced into the routine clinical practice. Until now, systemic administration of heparin has long been used to prevent thrombus formation in the circuit in the management of the extracorporeal circulation. Various adverse responses, such as hypotension, pulmonary hypertension, or thrombocytopenia, have been reported during the protamine reversal of heparin anticoagulation at the end of the extracorporeal circulation. Although such adverse hemodynamic effects of protamine can be critical in some patients, their precise mechanisms have not yet been fully elucidated. We … More , therefore, investigated the effects of protamine on vascular smooth muscle and endothelium, employing isometric tension recording methods. It was then found that only protamine itself, but not a heparin-protamine complex, has inhibitory actions on both vascular smooth muscle and endothelium. It was also suggested that protamine exert its inhibitory effects on vascular smooth muscle probably by stimulating the endothelium to release EDRF,by inhibiting the Ca^<2+> influx into the smooth muscle cell, and by inhibiting the Ca^<2+> release from the intracellular store of smooth muscle cell. Furthermore, it was suggested from the experiments with heparin that the inhibitory effects of protamine on vascular smooth muscle and endothelium are probably due to its positive charge, and that protamine presumably exert its direct vasodilating action without entering the smooth muscle cell. Previous reports have shown that free protamine exists in the blood during the heparin reversal besides a heparin-protamine complex. Putting the above findings together, it is suggested that the observed in vitro inhibitory effects of protamine on vascular smooth muscle and endothelium may partly explain the adverse hemodynamic effects of protamine occurred during the heparin reversal, and that the minimum possible amount of protamine should be administered slowly to reverse the heparin anticoagulation. Finally, our present data strongly suggest the importance of the determination of the amount of protamine required for the precise reversal of heparin anticoagulation, and the necessity of the early introduction of the "heparin-surfaced" circuit, which does not require the administration of protamine at the end of the extracorporeal circulation, into the clinical setting. Less
在体外循环的临床管理中,例如在心血管手术中的心肺转流中,预防血栓形成,即维持抗凝是相当重要的问题。虽然表面肝素化回路是一种新开发的抗血栓材料,据报道可有效维持体外循环期间的抗凝作用,但尚未将其引入常规临床实践。到目前为止,肝素的全身给药长期以来一直用于预防体外循环管理中回路中的血栓形成。在体外循环结束时使用鱼精蛋白逆转肝素抗凝期间,已报告了各种不良反应,如低血压、肺动脉高压或血小板减少症。虽然鱼精蛋白的这种不良血流动力学效应对某些患者可能是关键的,但其确切机制尚未完全阐明。我们 ...更多信息 因此,采用等长张力记录方法研究了鱼精蛋白对血管平滑肌和内皮的影响。然后发现,只有鱼精蛋白本身,而不是肝素-鱼精蛋白复合物,对血管平滑肌和内皮都具有抑制作用。鱼精蛋白对血管平滑肌的抑制作用可能是通过刺激内皮细胞释放EDRF、抑制平滑肌细胞内Ca^2+内流和抑制平滑肌细胞内Ca^2+释放等途径实现的。此外,从肝素的实验中可以看出,鱼精蛋白对血管平滑肌和内皮的抑制作用可能是由于其正电荷,鱼精蛋白可能不进入平滑肌细胞而直接发挥血管舒张作用。以往的报道表明,在肝素逆转过程中,除了肝素-鱼精蛋白复合物外,血液中还存在游离鱼精蛋白。综上所述,鱼精蛋白对血管平滑肌和内皮细胞的抑制作用可能部分解释了肝素抗凝过程中鱼精蛋白的不良血流动力学效应,提示在肝素抗凝过程中,应尽量减少鱼精蛋白的缓慢给药。最后,我们目前的数据强烈表明,确定精确逆转肝素抗凝所需的鱼精蛋白量的重要性,以及早期引入“肝素表面”回路的必要性,该回路不需要在体外循环结束时给予鱼精蛋白,进入临床环境。少
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
赤田 隆: "体外循環後のプロタミン投与量" 臨床麻酔. 16. 101 (1992)
Takashi Akada:“体外循环后的鱼精蛋白用量”临床麻醉。16. 101 (1992)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
T.Akata: "Heparin prevents the vasodilating actions of human small mesenteric arteries." Anesthesia and Analgesia.
T.Akata:“肝素可以防止人类肠系膜小动脉的血管舒张作用。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
K.Ariyoshi: "Giant cystic hygroma of the neck with difficult airway management. - A case report (in Japanese)" The Journal of Japan Society for Clinical Anesthesia.Vol.11. 90-95 (1991)
K.Ariyoshi:“气道管理困难的颈部巨大囊性水瘤。 - 病例报告(日语)”日本临床麻醉学会杂志第 11 卷。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KODAMA Kenji其他文献
KODAMA Kenji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KODAMA Kenji', 18)}}的其他基金
The thromboresistant mechanism of Heparin surface and its application to membrane oxygenator
肝素表面的抗血栓机制及其在膜式氧合器中的应用
- 批准号:
62480330 - 财政年份:1987
- 资助金额:
$ 1.6万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
Regenerative biomaterial patches for failing hearts
用于衰竭心脏的再生生物材料贴片
- 批准号:
MR/X024210/1 - 财政年份:2024
- 资助金额:
$ 1.6万 - 项目类别:
Fellowship
SBIR Phase I: A Novel Carbon-Sequestering Biomaterial for Dropped Ceiling Tiles
SBIR 第一阶段:用于吊顶瓷砖的新型碳封存生物材料
- 批准号:
2304384 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Standard Grant
A human tissue-engineered three-layer cornea (hTEC) supplemented with macrophages as a biomaterial for in vitro studies
补充有巨噬细胞的人体组织工程三层角膜(hTEC)作为体外研究的生物材料
- 批准号:
488980 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Operating Grants
System for Annulus Fibrosus Repair (SAFR) – a percutaneously implantable preformed biomaterial for the repair of defects caused by either degenerative disc disease or needle puncture during nucleus pulposus replacement procedures SAFR
纤维环修复系统 (SAFR) — 一种可经皮植入的预制生物材料,用于修复髓核置换手术期间因椎间盘退行性疾病或针刺造成的缺陷
- 批准号:
10051703 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Collaborative R&D
Development of a novel biomaterial model of collagen mediated genetic disease for study of collagen organisation and drug development
开发胶原蛋白介导的遗传病的新型生物材料模型,用于研究胶原蛋白组织和药物开发
- 批准号:
2897511 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Studentship
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer
免疫调节生物材料可增强 T 细胞对三阴性乳腺癌的反应
- 批准号:
10699815 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Bacterial Adhesion Inhibition and Biofilm Disruption by Adaptive Piezoelectric Biomaterial
自适应压电生物材料抑制细菌粘附和破坏生物膜
- 批准号:
10668030 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Highly Elastic Biomaterial Development for Urethral Application
尿道应用的高弹性生物材料开发
- 批准号:
10573094 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Biomaterial Manufacturing Suite in Support of NIH/NIAID and the Global Infectious Disease Research Community
支持 NIH/NIAID 和全球传染病研究界的生物材料制造套件
- 批准号:
10795293 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别:
Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression
通过生物材料驱动的免疫抑制减轻工程化 Aav 基因递送载体的免疫原性
- 批准号:
10741139 - 财政年份:2023
- 资助金额:
$ 1.6万 - 项目类别: